Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02182986 · ClinicalTrials.gov registry record

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
944
Enrollment target

NCT02182986 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 944 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02182986 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
944 participants
Enrollment target

Study Summary

Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to Epstein-Barr virus (EBV).

Interventions

  • PROCEDURE transplant
  • DRUG Immunosuppressive Drugs

Trial Details

FieldValue
Enrollment Target 944 participants
Start Date 2014-08-14
Est. Completion 2019-05-15

What the Registry Record Tells You About NCT02182986

The ClinicalTrials.gov registry entry for NCT02182986 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 944 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which transplant is the first listed.

NCT02182986 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02182986 about?

NCT02182986 is a clinical study titled "Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children". Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individual...

What is the current status of trial NCT02182986?

This trial is currently completed. The enrollment target is 944 participants. The study started on 2014-08-14. Estimated completion is 2019-05-15.

What interventions are being tested in trial NCT02182986?

The interventions under investigation include: transplant (PROCEDURE), Immunosuppressive Drugs (DRUG).

Who is sponsoring clinical trial NCT02182986?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.